1. Home
  2. IFF vs RPRX Comparison

IFF vs RPRX Comparison

Compare IFF & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Flavors & Fragrances Inc.

IFF

International Flavors & Fragrances Inc.

N/A

Current Price

$83.55

Market Cap

24.0B

Sector

Industrials

ML Signal

N/A

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

N/A

Current Price

$67.14

Market Cap

28.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IFF
RPRX
Founded
1833
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0B
28.4B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
IFF
RPRX
Price
$83.55
$67.14
Analyst Decision
Buy
Buy
Analyst Count
20
8
Target Price
★ $97.47
$65.38
AVG Volume (30 Days)
2.3M
★ 3.1M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
★ 1.85%
1.39%
EPS Growth
N/A
★ N/A
EPS
0.64
★ 1.03
Revenue
N/A
★ $2,378,193,000.00
Revenue This Year
N/A
$47.40
Revenue Next Year
$4.07
$9.10
P/E Ratio
$136.98
★ $65.59
Revenue Growth
N/A
★ 5.06
52 Week Low
$61.73
$37.31
52 Week High
$95.27
$67.71

Technical Indicators

Market Signals
Indicator
IFF
RPRX
Relative Strength Index (RSI) 35.63 71.41
Support Level $81.93 $55.48
Resistance Level $84.71 N/A
Average True Range (ATR) 2.45 1.48
MACD -1.05 0.34
Stochastic Oscillator 9.40 71.08

Price Performance

Historical Comparison
IFF
RPRX

About IFF International Flavors & Fragrances Inc.

International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations and partners with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrance producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients, though IFF plans to divest it in a deal expected to close in 2027.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: